EA201791895A1 - Дозы и способы введения телаванцина - Google Patents

Дозы и способы введения телаванцина

Info

Publication number
EA201791895A1
EA201791895A1 EA201791895A EA201791895A EA201791895A1 EA 201791895 A1 EA201791895 A1 EA 201791895A1 EA 201791895 A EA201791895 A EA 201791895A EA 201791895 A EA201791895 A EA 201791895A EA 201791895 A1 EA201791895 A1 EA 201791895A1
Authority
EA
Eurasian Patent Office
Prior art keywords
telavancin
methods
infection
patient
doses
Prior art date
Application number
EA201791895A
Other languages
English (en)
Inventor
Стивен Л. Бэрриэр
Артур Ло
Матай МАММЕН
Филип Уорбойз
Original Assignee
ТЕРЕВАНС БАЙОФАРМА АНТИБАЙОТИКС АйПи, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕРЕВАНС БАЙОФАРМА АНТИБАЙОТИКС АйПи, ЭлЭлСи filed Critical ТЕРЕВАНС БАЙОФАРМА АНТИБАЙОТИКС АйПи, ЭлЭлСи
Publication of EA201791895A1 publication Critical patent/EA201791895A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описаны новые дозы и способы введения телаванцина или его фармацевтически приемлемой соли пациенту-человеку с инфекцией, вызванной Staphylococcus aureus, такой как бактериемия, пневмония, эндокардит, остеомиелит, инфекция протезированного сустава или осложненная инфекция кожи и подкожной клетчатки. Также описаны способы лечения инфекции, вызванной Staphylococcus aureus, у пациента-человека с использованием телаванцина или его фармацевтически приемлемой соли. Доза телаванцина, вводимая пациенту, определяется, в частности, по весу и клиренсу креатинина пациента.
EA201791895A 2015-02-23 2016-02-18 Дозы и способы введения телаванцина EA201791895A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119592P 2015-02-23 2015-02-23
PCT/US2016/018396 WO2016137806A2 (en) 2015-02-23 2016-02-18 Doses and methods of administering telavancin

Publications (1)

Publication Number Publication Date
EA201791895A1 true EA201791895A1 (ru) 2018-01-31

Family

ID=55487131

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791895A EA201791895A1 (ru) 2015-02-23 2016-02-18 Дозы и способы введения телаванцина

Country Status (15)

Country Link
US (2) US20160243190A1 (ru)
EP (1) EP3261658B8 (ru)
JP (1) JP2018505910A (ru)
KR (1) KR20170123650A (ru)
CN (1) CN107257689A (ru)
AU (1) AU2016223090A1 (ru)
BR (1) BR112017017883A2 (ru)
CA (1) CA2976384A1 (ru)
EA (1) EA201791895A1 (ru)
HK (1) HK1245644B (ru)
IL (1) IL253791A0 (ru)
MX (1) MX2017010837A (ru)
TN (1) TN2017000358A1 (ru)
TW (1) TW201639590A (ru)
WO (1) WO2016137806A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
CN113035369B (zh) * 2021-03-10 2021-12-03 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
US20240024411A1 (en) * 2021-11-24 2024-01-25 Cumberland Pharmaceuticals Inc. Methods for the prevention or treatment of anthrax infection
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75083C2 (ru) 2000-06-22 2006-03-15 Тераванс, Інк. Производные гликопептидфосфонатов
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI312785B (en) 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI233932B (en) 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI342312B (en) 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
TWI641372B (zh) 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 使用抗生素治療超重和肥胖患者感染的方法

Also Published As

Publication number Publication date
US10751383B2 (en) 2020-08-25
WO2016137806A3 (en) 2016-10-20
WO2016137806A2 (en) 2016-09-01
MX2017010837A (es) 2017-12-07
HK1245644B (zh) 2019-12-06
IL253791A0 (en) 2017-09-28
JP2018505910A (ja) 2018-03-01
BR112017017883A2 (pt) 2018-07-17
TN2017000358A1 (en) 2019-01-16
US20180236027A1 (en) 2018-08-23
EP3261658B8 (en) 2019-06-05
AU2016223090A1 (en) 2017-08-24
EP3261658A2 (en) 2018-01-03
US20160243190A1 (en) 2016-08-25
KR20170123650A (ko) 2017-11-08
EP3261658B1 (en) 2019-04-03
TW201639590A (zh) 2016-11-16
CN107257689A (zh) 2017-10-17
CA2976384A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
EA201490254A1 (ru) Комбинированное лечение гепатита с
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
EA201791895A1 (ru) Дозы и способы введения телаванцина
EA201792566A1 (ru) Замещенные фенилоксазолидиноны для антимикробной терапии
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MY193963A (en) Composition for treating joint diseases and kit containing same
CY1120727T1 (el) Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου
MX2019002657A (es) Combinaciones con un peptido con esqueleto ciclado.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
BR112018072183A2 (pt) composição farmacêutica, e, método para prevenir uma doença de pele
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
EA202092278A1 (ru) Римегепант для связанных с cgrp расстройств
MX2017007652A (es) Metodo de tratamiento.
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
UA112832U (xx) Спосіб корекції функціонального стану печінки корів за фасціольозної інвазії
BR112017018977A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de uma infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, em um hospedeiro em necessidade do mesmo e para fabricação de um medicamento direcionado para uso terapêutico para tratamento de uma infecção pelo vírus da hepatite c, uso de um composto, e, formulação farmacêutica?.